Immunolabeling indicated that KCs treated with ASC-EVs exhibited varying degrees of protein for K5 (basal layer), K10 (suprabasal layer), and K16 (wound healing responsive) cytokeratins. This evidence concerns the gene KRT5 and dry eye syndrome.